Regeneration, Tutogen shareholders to decide merger on Feb. 27

By Lisa Kerner

Charlotte, N.C., Jan. 14 - Regeneration Technologies, Inc. and Tutogen Medical, Inc. will hold separate special meetings of shareholders on Feb. 27 at 9 a.m. ET to vote on the companies' proposed merger.

The meetings will take place in Alachua, Fla., where both companies have their headquarters.

The record date for Regeneration's meeting is Jan. 16, and Tutogen's record date is Jan. 22.

On Nov. 13, the boards of directors of Regeneration and Tutogen unanimously approved a definitive agreement to combine the two companies in a tax-free, stock-for-stock exchange valued at $263 million.

The Hart-Scott-Rodino waiting period in the merger expired on Jan. 7, according to a news release.

As previously reported, Tutogen shareholders will receive 1.22 shares of newly issued Regeneration common stock in exchange for each share of Tutogen common stock they own for an estimated value of $12.86 per share.

Regeneration stockholders will own about 55% of the combined company, and Tutogen stockholders will own roughly 45%.

Tutogen manufactures sterile biological implant products made from human (allograft) and animal (xenograft) tissue.

Regeneration processes allograft and xenograft tissue into shaped implants for use in orthopedic and other surgeries.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.